Hepato-biliary profile of potential candidate liver progenitor cells from healthy rat liver

Cédric Maerckx, Isabelle Scheers, Tatiana Tondreau, David Campard, Omar Nyabi, Mustapha Najimi, Etienne Sokal

Abstract

AIM: To evaluate the presence of progenitor cells in healthy adult rat liver displaying the equivalent advanced hepatic profile as that obtained in human.

METHODS: Rat fibroblastic-like liver derived cells (rFLDC) were obtained from collagenase-isolated liver cell suspensions and characterized and their phenotype profile determined using flow cytometry, immunocytochemistry, reverse transcription polymerase chain reaction and functional assays.

RESULTS: rFLDC exhibit fibroblastoid morphology, express mesenchymal (CD73, CD90, vimentin, α-smooth muscle actin), hepatocyte (UGT1A1, CK8) and biliary (CK19) markers. Moreover, these cells are able to store glycogen, and have glucose 6 phosphatase activity, but not UGT1A1 activity. Under the hepatogenic differentiation protocol, rFLDC display an up-regulation of hepatocyte markers expression (albumin, tryptophan 2,3-dioxygenase, G6Pase) correlated to a down-regulation of the expression of the biliary marker CK19.

CONCLUSION: Advanced hepatic features observed in human liver progenitor cells could not be demonstrated in rFLDC. However, we demonstrated the presence of an original rodent hepato-biliary cell type.

© 2012 Baishideng. All rights reserved.

Key words: Hepato-biliary profile; Hepatogenic differentiation; Liver; Progenitor cell; Rat

INTRODUCTION

Liver transplantation is considered to be the standard treatment for end-stage liver diseases. Unfortunately, clinical applications are restricted by the scarcity of organs and uncertainty about the very long-term success of the procedure.

In recent years, liver cell transplantation using hepatocytes was successfully performed in patients with inborn errors of metabolism as an alternative, or at least as a bridge to orthotopic liver transplantation[1-5]. However, the success of such a therapeutic approach remains limited by the quality of transplanted cells. In fact, cryopreservation procedures induce significant alterations at morphological
and functional levels of the thawed hepatocytes\(^6\)\(^7\).

To overcome these problems, several approaches to isolate and propagate liver stem or progenitor cells have been developed. In our laboratory, Najimi et al.\(^8\) isolated adult derived human liver stem/progenitor cells (ADHLSC) with hepato-mesenchymal profile. Under specific hepaticogenic conditions, these cells exhibit hepato-specific functions like glycogen storage, gluconeogenesis, urea synthesis, glucuronconjugation, and pharmacologic properties such as activity of phase I and II enzymes.\(^9\) These cells are also able to specifically engraft and differentiate into mature human hepatocytes in mouse liver parenchyma.\(^9\)

Preclinical studies using homologous animal models of human liver metabolic diseases are attractive. It is therefore a prerequisite to obtain homologous cells from syngenic animals to perform such studies. The relevance of using human progenitor cells in immunosuppressed animal models is indeed questionable.

In this context, we evaluated the presence of a liver progenitor cell in adult rat liver that would express the same specifications as the previously reported human progenitor cell, referred to as ADHLSC.

In the current study we isolated and characterized rat fibroblastic-like liver derived cells (rFLDC) from healthy adult rats. Characterization included proliferation rate, phenotype, genotype and hepatic-specific functional assays.

**MATERIALS AND METHODS**

**Rat fibroblastic-like liver derived cells**

Five male Wistar rats weighing ± 200 g were purchased from UCL Animalerie Centrales (Brussels, Belgium) and treated in accordance with the internal Animal Ethic and Welfare Committees (UCL/MD/2009/003).

We isolated rat liver parenchymal cells in a two-step collagenase A (1100 units/L) (Roche, Mannheim, Germany) perfusion procedure according to the Seglen method.\(^9\) We then obtained a hepatocyte enriched cell fraction following low-speed centrifugation (160 \(\times\) g/min for 3 min).

Viable hepatocytes, 1.5 million (> 75%, trypan blue exclusion), were seeded onto rat tail collagen I-coated plates (Greiner, Wemmel, Belgium) in Williams’ E medium (Invitrogen, Merelbeke, Belgium) supplemented with 10% fetal bovine serum (FBS) (AE Scientific, Marcq, Belgium), 25 \(\mu\)g/L human epidermal growth factor (EGF) (PeproTech, London, United Kingdom), 10 mg/L human insulin (Lilly, Brussels, Belgium), 1 \(\mu\)mol/L dexamethasone (Sigma, Bronem, Belgium), and 1% penicillin/streptomycin (P/S) (Invitrogen) at 37 °C in a fully humidified atmosphere containing 5% CO\(_2\). After 24 h we changed the medium in order to eliminate the non-adherent cells and thereafter we renewed it every 3 d. On days 7-12, hepatocytes died and small colonies of spindle-shaped fibroblastic cells emerged and proliferated. At this time, we switched the culture medium to Dulbecco’s modified Eagle’s medium (DMEM medium) [DMEM high glucose (Invitrogen) supplemented with 10% FBS and 1% P/S] in order to accelerate the proliferation of emerging cells. When cell cultures reached 90% confluence, we trypsinized them with 0.05% trypsin-1 mmol EDTA solution (Invitrogen) and replated them on a collagen-coated plate at a density of 10 \(\times\) 10\(^3\) cells/cm\(^2\). The medium was refreshed every 3 d.

Population doubling (PD) was evaluated after each passage using the following equation: \([\log (\text{harvested cells})/\log (\text{seeded cells})]\)/\(\log 2\). Cumulative population doubling (CPD) was calculated with the sum of PD at all passages.

At passages 2, 4 and 8, cells were analyzed using reverse transcription polymerase chain reaction (RT-PCR), immunocytochemistry and flow cytometry.

**Bone marrow mesenchymal stem cells**

We obtained bone marrow from Wistar rats by flushing the femur and tibia with ice cold phosphate-buffered saline (PBS) (Lonza, Verviers, Belgium) and isolated the cell fraction using Ficoll (GE Healthcare, Uppsala, Sweden) density gradient centrifugation at 340 \(\times\) g/min for 30 min.

Cells were then resuspended in alpha-MEM (Invitrogen) supplemented with 10% FBS (Perbio, Erembodegem, Belgium) and 1% P/S (Invitrogen) and seeded in 75 cm\(^2\) culture flasks. We removed non-adherent cells after 1 d and then refreshed the medium every 3-4 d. When cultures had reached 80%–90% confluence, we harvested the cells with 0.05% trypsin-1 mmol EDTA solution and replated them at a density of 7 \(\times\) 10\(^3\) cells/cm\(^2\). These cells were used as the internal control in mesodermal differentiation studies.

**Characterization of rFLDC**

**Flow cytometry:** Cells from the initial parenchymal fraction or after passaging were suspended at a concentration of 1000 cells/\(\mu\)L in PBS and 0.5% bovine serum albumin (BSA, Sigma) and then incubated for 25 min at room temperature with the following antibodies: CD29-PE (rabbit monoclonal, 1/70), CD44-FITC (mouse monoclonal, 1/20), CD45-FITC (mouse monoclonal, 1/20) (Abcam, Belgium), CD73-FITC (mouse monoclonal, 1/20), CD90-PE (mouse monoclonal, 1/20) (BD, Erembodegem, Belgium). Unspecific binding of antibodies, was evaluated using mouse IgG1 FITC and the PE isotypes control (BD).

We then washed and fixed them in cytofix/cytoperm (BD) until analysis with a FACSCanto II flow cytometer (BD).

**Immunocytochemistry:** We fixed rFLDC cultured on 24 well rat collagen type-1 coated plates with 3.5% formaldehyde (v/v, WVR, Leuven, Belgium) for 15 min at room temperature. After rinsing in PBS, we permeabilized cells with 1% Triton \(\times\) 100 (w/v Roche) in PBS for 10 min. Before incubation with specific rat antibodies, endogenous peroxidase activity was inhibited with PBS supplemented with 3% H\(_2\)O\(_2\) (VWR) solution for 3 min. Non-specific immunostaining was prevented by incubation with 3% BSA solution (Sigma) for 1 h. Cells were
then incubated for 1 h with 0.3% BSA containing the following antibodies: fibronectin (rabbit polyclonal, 1/50) (Dako, Heverlee, Belgium), vimentin (mouse monoclonal, 1/100), and α-smooth muscle actin (ASMA) (rabbit polyclonal, 1/100) (BD). After rinsing with PBS, cells were finally incubated for 30 min with Envision®, a secondary antibody against mouse or rabbit (Dako). Immunostaining results were evidenced by the addition of diamobenzidine and urea reagents (Sigma) and counterstained with Mayer hematoxylin solution.

RT-PCR analysis: We extracted total RNA from expanded or differentiated rFLDC using the TriPure isolation reagent (Roche) and carried out cDNA with the Thermoscript RT-PCR system (Invitrogen) using 1 μg total RNA, according to the manufacturer’s instructions. Rat specific primers used for gene amplification are listed in Table 1. We thereafter electrophoresed amplified cDNA on a 1% agarose gel (Invitrogen) followed by 0.01% ethidium bromide (Sigma) staining.

Plasticity assessment

**Hepatogenic differentiation:** rFLDC from passage four were seeded at a density of 10^4/cm^2 into 6 wells and 24 wells rat tail type I collagen-coated plates in the presence of expansion medium. When cell cultures reached 90% confluence, we switched the medium to Iscove’s modified Dulbecco’s medium (IMDM, Invitrogen), supplemented with 20 μg/L human EGF (Peprotech, London, United Kingdom) and 10 μg/L human basic fibroblast growth factor-2 (FGF2) (Peprotech) for 2 d. Thereafter, we subjected cells to differentiation induction for 10 d with IMDM containing 20 μg/L human hepatocyte growth factor (HGF) (Peprotech), 10 μg/L FGF2, nicotinamide 0.61 g/L (Sigma), and 1% insulin-transferrin-selenium (ITS) (Invitrogen). An intermediate step of differentiation/maturation in IMDM containing 20 μg/L human hepatocyte growth factor (HGF), 20 μg/L human oncostatin M (Peprotech), nicotinamide 0.61 g/L, and 1% ITS was performed over 10 d. For the subsequent maturation step of treatment with IMDM containing 20 μg/L oncostatin M, 1 μmol/L dexamethasone (Sigma), and 1% ITS premix for 10 d. For each step, we changed the medium every 3–4 d.

**Mesodermal differentiation:** At passages 0, 2, 4 and 8, rFLDC were plated at 1.5 × 10^4 cells/cm^2 on six-well rat tail collagen I-coated plates. At confluence, we performed osteogenic differentiation with complete DMEM medium containing 0.1 μmol/L ascorbate and 10 mmol/L β-glycerophosphate (Sigma). After 4 wk, calcium deposition was evidenced using alizarin red staining. For adipogenic differentiation, we incubated cells with expansion medium complete DMEM containing 1 μmol/L dexamethasone, and 0.5 mmol/L isobutylmethylxanthine, 0.2 mmol/L indomethacin (Sigma) and 10 μg/mL insulin (I. Lilly). Medium change was carried out twice a week. After 4 wk, oil red O staining revealed the presence of lipid vesicles. As a control of mesodermal differentiation capacity, the differentiation procedure was validated with rat bone marrow mesenchymal stem cells using α-MEM complete medium.

**Functional hepatic tests**

**Glycogen storage:** Undifferentiated and differentiated rFLDC fixed with 3.5% formaldehyde (Sigma) were incubated for 10 min in 1% periodic acid (Sigma). After washing with distilled water, the cells were incubated with Schiff’s reagent (Sigma) for 15 min. The preparations were then washed and mounted.

**Glucose-6-phosphatase activity:** We investigated glucose-6-phosphatase (G6Pase) activity in undifferentiated and differentiated rFLDC. After washing with PBS, cells were incubated for 4 h at 37 °C in 1.5 mL 50 mmol/L Tris (Sigma) and 50 mmol/L maleate (Sigma) buffer (pH

---

**Table 1 Primmers used for reverse transcription polymerase chain reaction**

| Gene    | Amplicon size (bp) | Primers                                                   |
|---------|--------------------|-----------------------------------------------------------|
| Vim     | 241                | F: AACGAGCGACTGAAACGATAA  
R: GACGCCATTTTACCTTGAGCC |
| Fos     | 392                | F: AGCTTGCGAGTATGGTTAG  
R: TGGAGAATGAGTTTGCTGCC |
| ASMA    | 385                | F: ATGGTCCTGAGCAGCATACT  
R: CAGCTTTCATCCAAGAAAGA |
| CK8     | 378                | F: TTAATGGAAGTCACAGGAGAC  
R: TTTGTTCGGACTGTAAGGTT |
| CK19    | 287                | F: GACGAGACATCCAGACACCATC  
R: ACTAATTTCTCCTCTGCTG |
| HNF4    | 332                | F: CAGTATTCTGGACAGTCGTG  
R: TACAGAGAAACATCTGATAG |
| TAT     | 275                | F: AGTGAGACATAGCAGCTATT  
R: GATCTTCTGCACAATAAGTGG |
| TDO     | 366                | F: CTTCTGTGACAGCATTCTCC  
R: CTGTTCGCTGGATACCTTA |
| aFP     | 289                | F: CAGTATTCTGGACAGTCGTG  
R: TACAGAGAAACATCTGATAG |
| Alb     | 365                | F: TTTAGGAGAAGATGCTGAGAG  
R: TTGTCAGGTACAGAGAGCA |
| UGT1A1  | 369                | F: CGTGTGGTTTTTTATAGG  
R: ACAAAAAATAGCACAGT |
| G6Pase  | 386                | F: GAAGATGTTTCTCGTGATAA  
R: AGTCCACATTACATTCTAGG |
| GAPDH   | 315                | F: CCATCAGGAACTGGTGGAT  
R: TIGTGAGAATGCAAAGGAC |
| CD29    | 321                | F: TTAATGGAACCTTGCTGGCTA  
R: AGTCTGCTGAAAATAAGTGG |
| CD44    | 383                | F: AGATTCTCCCCCAACATCTAG  
R: ACAGTCAGATGGAAAGATG |
| CD45    | 321                | F: TGAACATACAGGATGTTGAAAA  
R: TTGTCAGGTACAGAGAGCA |
| CD73    | 341                | F: ATAGTCACCCTGACAGATAAGG  
R: ATTTCATCTGGGCTTGCAG |
| CD90    | 380                | F: AAAGGACAAACAGGAACATCTC  
R: AAGCAAGCAGTCCAACACTCC |
| CD105   | 386                | F: TACCTCCGAAGACAGAGATC  
R: TCTGCTATATGGTGTTGCTGTA |

Fn: Fibronectin; Vim: Vimentin; ASMA: α-smooth muscle actin; CK: Cytokeratin; HNF4: Hepatocyte nuclear factor 4; TAT: Tyrosine aminotransferase; TDO: Tryptophan 2,3-dioxygenase; G6Pase: α-Fetoprotein; UGT1A1: UGT1A1 UDP-glucuronosyltransferase 1A1; Growth-6-phosphatase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
Characterization of rFLDC

All isolated rFLDC were analyzed and characterized after passages 2, 4 and 8 using FACS analysis and RT-PCR. Furthermore, a stable expression profile was observed up to P50 (data not shown).

Representative flow cytometry data at passage 4 demonstrated that the most described mesenchymal markers, CD73 and CD90 constituted 44% ± 36% and 71% ± 43% of the cell population, respectively (Figure 3), whereas the expression of CD29 protein was only detected in 2.4% ± 1.1%. The hematopoietic marker, CD45 (1.1% ± 0.6%) was almost undetectable.

To further characterize our cell population, we performed immunocytochemistry (ICC) for vimentin, fibronectin and ASMA proteins and compared the findings with rat bone marrow-derived mesenchymal stem cells (rBM-MSC) (Figure 4). The results indicated positive staining for ASMA, vimentin and fibronectin as observed with rBM-MSC.

To confirm the phenotypic profile of isolated rFLDC we performed RT-PCR analysis using specific mesodermal, hepatocyte and cholangiocyte markers at passage 4 (Figure 5).

The mesenchymal expression profile was confirmed by the detection of vimentin, fibronectin, ASMA, integrin β-1 (CD29), hyaluronic acid receptor (CD44), ecto 5'-nucleotidase (CD73), Thy-1 (CD90) and endoglin (CD105) mRNAs. RT-PCR also confirmed the absence of CD45 expression (Figure 5).

Because of their liver origin, rFLDC were also studied for their expression of hepatocyte and cholangiocyte markers. mRNA analysis revealed the expression of UDP-glucuronosyl transferase 1A1 (UGT1A1), cytokeratin 8 (CK8) and G6Pase (Figure 5). However, tyrosine aminotransferase (TAT), tryptophan 2,3-dioxygenase (TDO), albumin (Alb), α-fetoprotein (αFP) and hepatocyte nuclear factor 4 (HNF4) transcripts were not detected, all expressed by fully differentiated hepatocytes. mRNA analysis also revealed the expression of cytokeratin 19, a biliary marker.

In-vitro differentiation

First, we checked the ability of rFLDC to differentiate into adipocytes in the presence of specific media supplemented with dexamethasone, isobutyl-methylxanthine, indomethacin and insulin (Figure 6). We noticed that at early passages (P0-P2) two out of five rat fibroblastic-like liver derived cell cultures demonstrated a weak localized adipocytic differentiation. This ability was lost in further passages. Under osteogenic induction, no calcium deposits were noted (Figure 6).

In order to demonstrate their potential to differentiate into mature hepatocytes we seeded 10⁵ cells/cm² from passage 4 in serum free-medium in the presence of several “hepatogenic” factors, as described in the Materials and Methods section. After 32 d, cells showed a slight morphology change and few cells adopted a polygonal shape (Figure 7). Using RT-PCR, we compared the expression of immature and mature hepatocytic/biliary mRNA on undifferentiated and differentiated rFLDC (Figure 5). Despite a variation in serum concentration (10% vs 2%) between the expansion medium and hepatogenic control medium, respectively, no differences in mRNA expression
were noted (data not shown). Interestingly, differentiated rFLDC lost the expression of CK19, a biliary marker. Moreover, differentiated rFLDC acquired the expression of mature hepatocyte lineage markers including TDO and albumin.

To test their liver metabolic activity, we explored their ability to store glycogen and to perform glucogenesis (G6Pase activity) and their potential to conjugate bilirubin.

Glycogen storage, evidenced by periodic-acid shift staining, showed that, like rat hepatocytes (Figure 8A), undifferentiated and differentiated cells can store glycogen (Figure 8B and C).

As shown at Figure 8D-F, rat hepatocytes and rFLDC cells also revealed a basal G6Pase activity. These results were corroborated by the expression of G6Pase at the mRNA level.

In addition to glycogen storage and G6Pase activity we assessed the ability of differentiated and undifferenti-
Maerckx C et al. Isolation of progenitor cells from rat liver

Figure 4 Rat fibroblastic-like liver derived cells mesenchymal characterization by immunocytochemistry. A-C: Rat bone marrow mesenchymal stem cells (MSC); D-F: Rat fibroblastic-like liver derived cells. ASMA: α-smooth muscle actin.

Figure 5 Representative reverse transcription-polymerase chain reaction characterization of undifferentiated and differentiated rat fibroblastic-like liver derived cells in comparison with rat hepatocyte suspension. Hepatic markers: Cytokeratin 8 (CK8), hepatic nuclear factor 4 (HNF4), tyrosine aminotransferase (TAT), tryptophan 2,3-dioxygenase (TDO), α-fetoprotein (αFP), albumin (Ab), UDP glucuronosyltransferase 1A1 (UGT1A1), glucose-6-phosphatase (G6Pase); Biliary marker: CK19; Mesenchymal markers: Vimentin (Vim), fibronectin (Fn), α-smooth muscle actin (ASMA); Cell surface markers: Integrin β-1 (CD29), hyaluronic acid receptor (CD44), tyrosine phosphatase (CD45), ecto-5-nucleotidase (CD73), Thy-1 (CD90), endoglin (CD105); Housekeeping gene: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

DISCUSSION

Because preclinical studies use animal models mimicking human diseases, we tried to isolate from rodent liver a liver progenitor cell that would display characteristics reported for ADHLCSC. The use of human derived cells in animal models is considered irrelevant, as they may not engraft and function similarly in a xenogenic rodent environment.

Like human cells, rFLDC were isolated and emerged in vitro after culture of liver cell suspension following enzymatic-mediated disaggregation of liver. However, many differences were observed: rFLDC demonstrated a higher proliferative potential and did not reach senescence after at least 50 passages in contrast to human cells which stopped proliferating after 10-12 passages[13]. rFLDC were able, at early passages, to differentiate into adipocytes, in contrast to ADHLCSC.

Like human cells, rFLDC displayed a mesenchymal profile as evidenced by the expression of CD44, CD73, CD90 and CD105. The cell population was not contaminated by hematopoietic stem cells as evidenced by the absence of CD45 expression. These results confirmed the presence of a new enriched cell population different from the freshly isolated hepatic cells. RT-PCR also revealed expression of CK8, UGT1A1 and G6P under...
lining their hepatic-like profile. Undifferentiated rFLDCs have the capacity to store glycogen and show G6Pase activity as mature hepatocytes.

In a hepatogenic differentiation medium, low numbers of rFLDC display the polygonal morphology of mature hepatocytes. Differentiated rFLDC express both albumin and TDO. However, we did not observe the expression of more specific hepatic markers such as HNF4 or TAT.

Candidate progenitor cells reported in this study were isolated from healthy rat livers, in contrast to other progenitor liver cells described elsewhere, such as oval cells, obtained after submitting animals to carcinogenic agents or toxic injuries. Stellate cells and rFLDC share common features like the expression of vimentin, ASMA, CK19, and CD90, although no expression of αFP was detected in rFLDC.

Differentiated rFLDC do not express CK19 or αFP, and differ therefore from small hepatocytes and epithelial cells also recovered from normal livers.

Recently, Sahin et al., using a 2-step collagenase protocol, reported a cell population derived from adult rat liver and called them LDPCs (liver-derived progenitor cells). Regarding their oval morphology and expression of HNF3β, CD45, CD34 and CD90, these cells seem to be closely related to oval cells despite the absence of CK7, CK8 and CK19 expression.

In conclusion our results showed that rodent progenitor cells homologous to ADHLSC can not easily be obtained even when the same isolation and culture protocol was applied using a rat model. However, this protocol allowed the isolation of a novel type of liver progenitor cell population with both hepatic and biliary phenotype including G6Pase activity, glycogen storage, CK8, UGT1A1 and CK19 expression.

In the presence of a hepatogenic differentiation medium, rFLDC lose the CK19 biliary marker, but do not acquire a more mature hepatic status possibly due to the use of human cytokines and growth factors, which may not be appropriate for rodent precursors, stressing again the difficulty in generating homologous models.

Further characterization and in vitro hepatogenic differentiation improvement are required before their relevant use in preclinical studies.
Background

Liver cell transplantation using hepatocytes was successfully performed in patients with inborn errors of metabolism. However, the success of such a therapeutic approach remains limited by the quality of transplanted cells. To overcome these problems several approaches to isolate and propagate liver stem or progenitor cells have been developed. The capacity of those cells to restore a liver metabolic function must be demonstrated.

Research frontiers

Preclinical studies using homologous animal models of human liver metabolic diseases are attractive. It is therefore a prerequisite to isolate and propagate human homologous liver stem or progenitor cells from syngenic animals to perform such studies. In this study, the authors showed that rodent progenitor cells homologous to human adult-derived liver stem/progenitor cells can not easily be obtained even when the same protocol was applied.

Innovations and breakthroughs

In this study, the authors reported the isolation of novel potential candidate liver progenitor cells isolated from healthy rat liver called rat fibroblastic-like liver derived cells (rFLDC). These cells express both hepatic and biliary phenotype and...
are able to acquire some hepatic characteristics in the presence of hepatogenic differentiation medium.

**Applications**

Isolation and characterization of progenitor/stem cells would be very useful to assay the in-vivo efficacy of liver mesenchymal progenitor cells in syngeneic animal models of liver metabolic diseases, particularly in the Gunn rat, a model of hyperbilirubinemia.

**Peer review**

This study shows that the advanced hepatic features of human liver progenitor cells have not been demonstrated in rFLDC. Although it strengthens the unique specificity of these human liver progenitor cells, it also shows that homologous cells have not been demonstrated in rFLDC. This study shows that the advanced hepatic features of human liver progenitor cells can not easily be developed even when the same isolation and culture protocols are applied. The authors should make a comparison of their cells with human established liver cells.

**REFERENCES**

1. Muraca M, Gerunda G, Neri D, Vilei MT, Granato A, Feltracco P, Meroni M, Giron G, Burlina AB. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. *Lancet* 2002; **359**: 317-318
2. Najimi M, Sokal E. Update on liver cell transplantation. *J Pediatr Gastroenterol Nutr* 2004; **39**: 311-319
3. Najimi M, Sokal E. Liver cell transplantation. *Minerva Pediatr* 2005; **57**: 243-257
4. Sokal EM, Smets F, Bourgeois A, Van Maldergem L, Buts JP, Reding R, Bernard Otte J, Evrard V, Latinne D, Vincent MF, Moser A, Soriano HE. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. *Transplantation* 2003; **76**: 735-738
5. Strom SC, Fisher RA, Thompson MT, Sanyal AJ, Cole PE, Ham JM, Posner MP. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. *Transplantation* 1997; **63**: 559-569
6. Stéphenne X, Najimi M, Sokal EM. Hepatocyte cryopreservation: is it time to change the strategy? *World J Gastroenterol* 2010; **16**: 1-14
7. Stéphenne X, Najimi M, Ngoc DK, Smets F, Hue L, Guigas B, Sokal EM. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. *Cell Transplant* 2007; **16**: 409-419
8. Najimi M, Khoo DN, Lysy PA, Jazouli N, Abarca J, Sempoux C, Sokal EM. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? *Cell Transplant* 2007; **16**: 717-728
9. Khoo DN, Scheers I, Eherts S, Jazouli N, Nyabi O, Buc-Calderon P, Meulemans A, Nussler A, Sokal E, Najimi M. In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: a potential tool for in vitro pharmacotoxicological testing. *Cell Transplant* 2011; **20**: 287-302
10. Seglen PO. Preparation of isolated rat liver cells. *Methods Cell Biol* 1976; **13**: 29-83
11. Sokal EM, Trivedi P, Portmann B, Movat AP. Developmental changes in the intra-acinar distribution of succinate dehydrogenase, glutamate dehydrogenase, glucose-6-phosphate, and NADPH dehydrogenase in the rat liver. *J Pediatr Gastroenterol Nutr* 1989; **8**: 522-527
12. Muraca M, Blancaart N. Liquid-chromatographic assay and identification of monos- and diester conjugates of bilirubin in normal serum. *Clin Chem* 1983; **29**: 1767-1771
13. Scheers I, Maerckx C, Khoo N, Marcelle M, Decottignies N, Najimi M, Sokal E. Human liver progenitor cells in long term culture maintain appropriate gatekeepers mechanisms against transformation. In press
14. Qin AL, Zhou XQ, Zhang W, Yu H, Xie Q. Characterization and enrichment of hepatic progenitor cells in adult rat liver. *World J Gastroenterol* 2004; **10**: 1480-1486
15. Yin L, Sun M, Ilc Z, Leffert HL, Sell S. Derivation, characterization, and phenotypic variation of hepatic progenitor cell lines isolated from adult rats. *Hepatology* 2002; **35**: 315-324
16. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, Dabeva MD. Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. *Hepatology* 2008; **47**: 636-647
17. Nagai H, Terada K, Watanabe G, Ueno Y, Aiba N, Shibuya T, Kawagoe M, Kameda T, Sato M, Senoo H, Sugiyama T. Differentiation of liver epithelial (stem-like) cells into hepatocytes induced by coculture with hepatic stellate cells. *Biochim Biophys Acta* 2002; **1593-1605**
18. Tateno C, Yoshizato K. Growth and differentiation in culture of clonogenic hepatocytes that express both phenotypes of hepatocytes and biliary epithelial cells. *Am J Pathol* 1996; **146**: 1420-1425
19. Sahin MB, Schwartz RE, Buckley SM, Heremans Y, Chase L, Hu WS, Verfaillie CM. Isolation and characterization of a novel population of progenitor cells from unmanipulated rat liver, *Liver Transpl* 2008; **14**: 333-345
20. Geerts A, Niki T, Hellemans K, De Craemer D, Van Den Berg K, Lazou JM, Stange G, Van De Winkel M, De Besler P. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. *Hepatology* 1998; **27**: 590-598

S-Editor Cheng JX L-Editor Webster JR E-Editor Zheng XM